Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE) First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...